Apply Now: 📣 BLUE KNIGHT ™️ Resident QuickFire Challenge: Accelerating Project NextGen

Johnson & Johnson Innovation, together with the Biomedical Advanced Research and Development Authority (BARDA), is proud to launch the BLUE KNIGHT™ Resident QuickFire Challenge: Accelerating Project NextGen.

Current and alumni Blue Knight residents and their collaborators are invited to submit promising potential pre-clinical or clinical solutions for the opportunity to receive award funding from a total pool of $10M to help them accelerate their potential vaccines, therapeutics, and enabling technologies.

Applicants can apply to one or both application tracks:

  • Partner: Forging collaborations can accelerate evidence generation to get to key inflection points, allowing for more rapidly deployable potential solutions that provide mutual value. For the ‘Partner’ track of this challenge, Blue Knight residents who choose to collaborate with another Blue Knight or early-stage company in their submission may apply through a joint application submission.*
  • Sole Contributor: Blue Knight residents are invited to apply to accelerate their potential solution.**

All awards are subject to the execution of the necessary (award) agreements.

*Applicants must have at least one Blue Knight resident, current or alumni, as a collaborator
**Applicants must be current or alumni Blue Knight residents


Learn more here.

Recent News


ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous


U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure

Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to develop the latest generation pralidoxime chloride auto-injector as a countermeasure against organophosphate or nerve agent poisoning.


Activation Capital Welcomes Dr. Jim Pannucci as its Vice President of Entrepreneurship

Activation Capital, an innovation ecosystem development organization, announced today that it has appointed Jim Pannucci, Ph.D., PMP as its Vice President of Entrepreneurship. As the new Vice President of Entrepreneurship, Dr. Pannucci will help Activation Capital continue to grow a deep talent base of life sciences entrepreneurs operating in the region and help empower them